Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis

被引:267
作者
Jia, SH
Li, Y
Parodo, J
Kapus, A
Fan, LZ
Rotstein, OD
Marshall, JC
机构
[1] Univ Hlth Network, Toronto Gen Hosp, Sepsis Res Labs, Toronto, ON M5G 2C4, Canada
[2] Univ Toronto, Dept Surg, Toronto, ON, Canada
[3] Hosp Sick Children, Toronto, ON M5G 1X8, Canada
[4] Univ Toronto, Interdept Div Crit Care Med, Toronto, ON, Canada
关键词
D O I
10.1172/JCI200419930
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Pre-B cell colony-enhancing factor (PBEF) is a highly conserved 52-kDa protein, originally identified as a growth factor for early stage B cells. We show here that PBEF is also upregulated in neutrophils by IL-1beta and functions as a novel inhibitor of apoptosis in response to a variety of inflammatory stimuli. Induction of PBEF occurs 5-10 hours after LPS exposure. Prevention of PBEF translation with an antisense oligonucleotide completely abrogates the inhibitory effects of LPS, IL-1, GM-CSF, IL-8, and TNF-alpha. on neutrophil. apoptosis. Immunoreactive PBEF is detectable in culture supernatants from LPS-stimulated neutrophils, and a recombinant PBEF fusion protein inhibits neutrophil apoptosis. PBEF is also expressed in nentrophils from critically ill patients with sepsis in whom rates of apoptosis are profoundly delayed. Expression occurs at higher levels than those seen in experimental inflammation, and a PBEF antisense oligonucleotide significantly restores the normal kinetics of apoptosis in septic polymorphonuclear neutrophils. Inhibition of apoptosis by PBEF is associated with reduced activity of caspases-8 and -3, but not caspase-9. These data identify PBEF as a novel inflammatory cytokine that plays a requisite role in the delayed neutrophil apoptosis of clinical and experimental sepsis.
引用
收藏
页码:1318 / 1327
页数:10
相关论文
共 67 条
[1]   REMOVAL OF ENDOTOXIN FROM PROTEIN SOLUTIONS BY PHASE-SEPARATION USING TRITON X-114 [J].
AIDA, Y ;
PABST, MJ .
JOURNAL OF IMMUNOLOGICAL METHODS, 1990, 132 (02) :191-195
[2]   Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care [J].
Angus, DC ;
Linde-Zwirble, WT ;
Lidicker, J ;
Clermont, G ;
Carcillo, J ;
Pinsky, MR .
CRITICAL CARE MEDICINE, 2001, 29 (07) :1303-1310
[3]  
BENNETT CF, 1992, MOL PHARMACOL, V41, P1023
[4]   Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].
Bernard, GR ;
Vincent, JL ;
Laterre, P ;
LaRosa, SP ;
Dhainaut, JF ;
Lopez-Rodriguez, A ;
Steingrub, JS ;
Garber, GE ;
Helterbrand, JD ;
Ely, EW ;
Fisher, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709
[5]   Sepsis and evolution of the innate immune response [J].
Beutler, B ;
Poltorak, A .
CRITICAL CARE MEDICINE, 2001, 29 (07) :S2-S6
[6]   DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ .
CHEST, 1992, 101 (06) :1644-1655
[7]   HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma [J].
Brezniceanu, ML ;
Völp, K ;
Bösse, S ;
Solbach, C ;
Lichter, P ;
Joos, S ;
Zörnig, M .
FASEB JOURNAL, 2003, 17 (08) :1295-+
[8]   Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays [J].
Bustin, SA .
JOURNAL OF MOLECULAR ENDOCRINOLOGY, 2000, 25 (02) :169-193
[9]   FADD, A NOVEL DEATH DOMAIN-CONTAINING PROTEIN, INTERACTS WITH THE DEATH DOMAIN OF FAS AND INITIATES APOPTOSIS [J].
CHINNAIYAN, AM ;
OROURKE, K ;
TEWARI, M ;
DIXIT, VM .
CELL, 1995, 81 (04) :505-512
[10]   The immunopathogenesis of sepsis [J].
Cohen, J .
NATURE, 2002, 420 (6917) :885-891